Alaska Vaccine-Preventable Disease Surveillance Report 3rd Quarter 2023 (July-September)

The purpose of this report is to provide timely vaccine-preventable disease information to health care providers and other stakeholders for situational awareness.

Summary of Reported Cases of Select Vaccine-Preventable Disease, Alaska

	Anch	Mat- Su	Gulf Coast	Interior	Northern	Southeast	South west	2023 Q3 (Jul-Sep) Total *†	2023 YTD Total	2022 Total *†	2021 Total *†
Haemophilus influenzae, invasive disease	0	0	0	0	0	0	3	3	17	36	15
Hepatitis A	0	0	0	0	0	0	0	0	0	2	1
Hepatitis B, acute	0	0	0	0	0	0	0	0	2	1	2
Measles	0	0	0	0	0	0	0	0	0	0	0
Meningococcal invasive disease	1	0	0	0	0	0	0	1	1	0	1
Mumps	1	0	0	0	0	0	0	1	1	1	0
Pertussis	0	2	1	0	0	0	0	3	4	2	1
Pneumococcal invasive disease	18	6	6	6	1	1	6	44	158	250	185
Rubella	0	0	0	0	0	0	0	0	0	0	0
Tetanus	0	0	0	0	0	0	0	0	0	0	0
Varicella	1	2	0	0	0	0	0	3	19	32	15

^{*}Counts are provisional and may be updated.

Haemophilus influenzae, invasive disease

During the July-September 2023 period, 3 cases were reported to the Alaska Section of Epidemiology (SOE):

- 3/3 (100%) of the cases were confirmed by culture from normally sterile sites
- Isolate serotypes: 3 Hia
- None of the isolates serotyped from cases involving children <5 years of age were vaccine-preventable

Age Group (years)	No. Cases	No. Cases Hib Vax Up-to-Date (UTD) [±]
<2	2 (67%)	2 (100%)
2-4	0	0
<u>≥</u> 5	1 (33%)	N/A

Meningococcal invasive disease

During the July-September 2023 period, 1 case was reported to the Alaska Section of Epidemiology (SOE):

• The confirmed case occurred in a 16–23-year-old, unvaccinated individual. We were unable to determine the serogroup from the clinical specimen.

Mumps

During the July-September 2023 period, 1 case was reported to the Alaska Section of Epidemiology (SOE):

• The probable case occurred in a 19-64-year-old vaccinated individual who had no recent travel history.



[†]Includes confirmed and probable cases.

Pertussis

During the July-September 2023 period, 3 cases were reported to the SOE:

• 2 cases were laboratory-confirmed by PCR, and one was epi-linked to one of the laboratory-confirmed cases

Age Group (years)	No. Cases	No. Cases Pertussis Vax Up-to-Date UTD [±]
<15	2 (67%)	0
15-19	0	0
20-29	1 (33%)	1 (100%)
30-39	0	0
40-49	0.	0
50-59	0	0
<u>>60</u>	1	0

Invasive pneumococcal disease

During the July-September 2023 period, 44 cases were reported to the SOE:

• All cases were confirmed by either PCR or culture isolation of Streptococcus pneumoniae from a normally sterile body site

Age Group (years)	No. Cases
<2	0
2-4	2 (5%)
5-18	1 (2%)
19-64	29 (66%)
>65	12 (27%)

Varicella

During the July-September 2023 period, 3 cases were reported to the SOE:

- 2 (67%) were confirmed by viral culture or PCR, and one was epi-linked to a herpes zoster case
- No outbreaks were reported

Age Group (years)	No. Cases	No. Cases VAR Vax UTD [±]
< 1	3 (100%)	N/A
1-6	0	2 (50%)
7-10	0	0
11-19	0	0
≥ 20	0	0

Effective 9/3/2023, Alaska Division of Public Health reporting requirements were updated. Individual suspected or confirmed varicella (chickenpox) infections are no longer reportable to public health by laboratories or health care providers. Varicella deaths must be reported by health care providers (7 AAC 27.005)

VPD Updates and Reminders

- Measles: For the latest surveillance data from CDC visit: http://www.cdc.gov/measles/cases-outbreaks.html
- Mumps: For the latest surveillance data from CDC visit: http://www.cdc.gov/mumps/outbreaks.html
- Conditions reportable to public health in Alaska, available at: https://health.alaska.gov/dph/Epi/Pages/pubs/conditions/default.aspx
- Recommended immunizations for children and adults, and administration schedules: https://health.alaska.gov/dph/Epi/iz/Pages/parents.aspx
- Cases are defined according to national standards: https://ndc.services.cdc.gov/

VPD Surveillance Coordinator Contact: Stephanie Massay, Phone 907-269-8011, Email stephanie.massay@alaska.gov



^{*}Based upon the Advisory Committee on Immunization Practice's routine age-appropriate immunization recommendations for children and adults who are not at increased risk for this disease.